M&A
confidence high
sentiment positive
materiality 0.70
Xtant completes $17M acquisition of Surgalign SPV's Coflex/CoFix product lines
Xtant Medical Holdings, Inc.
- Purchase price $17M in cash; funded with cash on hand and $5M from existing term loan.
- Surgalign SPV 2021 revenue $17.8M, revenues in excess of direct expenses $8.0M.
- Pro forma 2021 net income $0.4M vs Xtant standalone net loss $4.8M; accretive.
- Acquired Coflex/CoFix FDA-approved for lumbar spinal stenosis, minimally invasive.
- Transaction closed Feb 28, 2023; abbreviated financials filed May 16, 2023.